Comorbidity patterns and mortality in HFpEF: A retrospective longitudinal cohort study
In HFpEF, comorbidities are common and associated with higher mortality, especially within the first 3 years. Prognostic effects persisted across GWTG strata, while SGLT2i therapy attenuated these risks, highlighting the importance of early detection and optimized therapy.
Authors
- Sumit Bhagra (ORCID: https://orcid.org/0000-0003-3470-018X)
- Ebrahim Barkoudah (ORCID: https://orcid.org/0000-0001-8224-5121)
- Rani Chikkanna
- Ali R. Yazdanyar (ORCID: https://orcid.org/0000-0001-5935-4055)
- Zeliang Ma (ORCID: https://orcid.org/0000-0001-8250-0540)
- Mohamad H. Yamani (ORCID: https://orcid.org/0000-0002-3567-8773)
- Gregg C. Fonarow (ORCID: https://orcid.org/0000-0002-3192-8093)
- Mohammed Yousufuddin (ORCID: https://orcid.org/0000-0002-7496-9856)
- Khalid Benkhadra
- Muhammad Waqas Tahir (ORCID: https://orcid.org/0000-0002-8643-9852)
Institutions
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Hospital of the University of Pennsylvania (US)
- Albert B. Chandler Hospital (US)
- Jacksonville College (US)
- Mayo Clinic Health System (US)
- Baystate Health (US)
- Mayo Clinic Hospital (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- International Journal of Cardiology Cardiovascular Risk and Prevention
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1016/j.ijcrp.2025.200526
- Citations
- 1
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.39